Can Deep Learning Survive the Precision Medicine Paradox?
As precision medicine narrows patient cohorts to rare‑disease scales, deep learning models face a paradox of data scarcity and overfitting that threatens the future of clinical AI.
Articles, expert interviews, and insights from life sciences leaders
Could Biological Ageing Be the Next Big Shift in Drug Discovery?
“The pharma industry is beginning to look at biological age as a surrogate endpoint to improve clinical trials."
Read interview: How Should Pharma Companies Audit AI Vendors?
Read interview: Could Biological Ageing Be the Next Big Shift in Drug Discovery?
Read interview: Is AI Quietly Creating a GDPR Crisis in Clinical Research?
Read interview: How AI Is Reshaping Data Integrity in Pharma Manufacturing
Read interview: AI in Pharma: Why the Future of Healthcare Starts With Patients, Not Tech
Read interview: AI in Pharma: Hype vs. What Actually Works
Read interview: How Pharmacy Innovation Is Changing Healthcare Delivery
Read interview: The Role of Regulatory Leadership in Healthcare
Exclusive Pharmatica Content
Explore expert-led podcasts, pharmaceutical intelligence, life sciences insights and research-driven analysis from leading industry voices. Pharmatica delivers trusted biotech news, drug development trends and commercial intelligence for professionals across the pharmaceutical sector.
Operation TrialBlazer: Can the U.S. Reclaim Clinical Trial Leadership?
Operation TrialBlazer aims to reignite U.S. clinical development by accelerating trials, modernising FDA oversight, and strengthening pharmaceutical innovation.
Genomic Governance Ensures Equity at the Core of Drug Discovery
Discover why genomic equity is essential for reliable AI-driven drug discovery, precision medicine, and building more representative pharmaceutical innovation.
FDA Registration for Drug Manufacturing Enters a New Era
The FDA's proposed drug manufacturing modernisation rule could accelerate distributed manufacturing, digital quality systems, and pharma supply chain resilience.
AAV Vector Manufacturing: Solving Gene Therapy's Bottleneck
Discover how innovations in AAV vector manufacturing are improving scalability, quality, and commercial readiness for next-generation gene therapies.
11 Clinical Trials Defining Pharmaceutical Strategy in 2026
We've mapped the competitive, regulatory, and commercial stakes of the top 11 clinical trials that have defined pharma strategy so far in 2026.
Anthropic’s Big AI Drug Discovery Announcement
Anthropic's new drug discovery programme marks a strategic shift from sole AI software provider to active R&D participant. Here's what it means for pharmaceutical innovation.
Digital Measures in Clinical Trials: FDA vs EMA Pathways
Explore how novel digital measures gain regulatory acceptance in clinical trials, comparing FDA-structured pathways with EMA engagement-led frameworks.
FDA Draft Guidance on Gene Editing Safety (2026)
The FDA’s 2026 gene editing draft guidance could change your regulatory strategy. Explore the new NGS requirements for cell and gene editing therapies.
Next-Generation Sequencing for Cell Line Development in Biologics Manufacturing
Discover how next-generation sequencing in cell line development is improving biologics manufacturing, quality control, and regulatory confidence.
Real-Time Clinical Trials Are a Huge Competitive Advantage
Real-time clinical trials enable continuous data capture and faster decisions, improving how data is used in clinical trials. Here is what pharma leaders need to know.
Optimising Preclinical Pharmacology for Oncology NMEs
Over 90% of oncology NMEs that succeed in animal studies fail in clinical trials. This analysis examines how to optimise preclinical pharmacology models to improve translational success.
